NCT05198284View on ClinicalTrials.gov

Prospective Decision Impact Clinical Utility Trial of KidneyIntelX

Active, not recruitingOBSERVATIONAL
Enrollment

2,000

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

December 1, 2023

Study Completion Date

November 1, 2026

Conditions
Diabetic Kidney DiseaseChronic Kidney DiseasesChronic Kidney Disease Stage 1Chronic Kidney Disease Stage 2Chronic Kidney Disease Stage 3
Interventions
DIAGNOSTIC_TEST

KidneyIntelX

KidneyIntelX is a blood-based clinical diagnostic tool that assesses the risk of progressive kidney function decline in chronic kidney disease patients with type 2 diabetes.

Trial Locations (1)

10029

Mount Sinai Health System, New York

All Listed Sponsors
lead

Renalytix AI, Inc.

INDUSTRY